Streetbeat News

Products Services

ACN

SAP

Accenture Plc (NYSE:ACN) is set to acquire Ammagamma, an Italian AI firm, to enhance its European AI capabilities. The acquisition aligns with Accenture's $3 billion investment plan to aid client transformation through AI. Ammagamma brings a team of 90 AI professionals to Accenture's Advanced Center for AI in Europe. Additionally, Accenture announced a collaboration with SAP SE (NYSE:SAP) to reinvent supply chains, aiming to reduce risk and support sustainability. Accenture's cash position was $9.04 billion as of August 31, 2023. ACN shares closed slightly lower at $332.43.

Portfolio Pulse from Shivani Kumaresan

November 28, 2023 | 1:15 pm

GEHC

ICAD

iCAD, Inc. has announced that its applications from the iCAD Breast Health Suite are now integrated into GE HealthCare's MyBreastAI Suite. This integration is expected to enhance the capabilities of GE HealthCare's suite by incorporating iCAD's advanced breast health technologies.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:13 pm

LCFY

Locafy Limited (NASDAQ: LCFY), a SaaS company specializing in local search engine marketing, announced promising trial results for its Article Accelerator product. The trials, conducted with a major U.S.-based media publisher, showed significant increases in online visibility metrics for advertorials. The technology led to up to 71% increases in impression and visitor counts and a 193% increase in keyword rankings. Locafy's CEO, Gavin Burnett, expressed confidence in the technology's market potential and its ability to offer value to media organizations. The company has restructured its teams for scalable production and is conducting additional trials with a second media partner.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:13 pm

CRL

Charles River Laboratories International, Inc. (NYSE:CRL) and Genetic Cures for Kids Inc (GC4K) have announced a collaboration for plasmid DNA production to support early phase trials for SPG56 Hereditary Spastic Paraplegia. Charles River will utilize its eXpDNA™ platform and HQ Plasmid Manufacturing Center of Excellence to aid in the development of a gene therapy for SPG56, a rare neurodegenerative disease with no current treatment. The partnership aims to create a framework for treating other genetic diseases.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:12 pm

TMO

Thermo Fisher Scientific has formed a strategic partnership with Flagship Pioneering to develop and scale multiproduct platforms aimed at accelerating the creation of first-in-class therapies. This collaboration builds on their existing supply relationship and will leverage both companies' expertise in life science tools, diagnostics, and services to support the biotech ecosystem.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:10 pm

AMPS

Brightcore Energy has partnered with Altus Power, Inc. (NYSE:AMPS) and Brennan Investment Group on a new community solar project. The project involves installing solar panels across 19 properties, expected to produce 8,993MWh of electricity annually. The 7.5-megawatt rooftop system is set to be completed next month, contributing to significant CO2 emissions reductions. Altus Power's role as a leading clean electric power provider is highlighted, along with the project's alignment with New Jersey's growing community solar program.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:10 pm

NUWE

Nuwellis, Inc. (NASDAQ:NUWE) announced new real-world data showing positive responses in pediatric patients with fluid overload to its Aquadex ultrafiltration therapy with continuous hematocrit monitoring. The study, published in Pediatric Nephrology, demonstrated successful treatment without complications. The therapy is FDA-cleared for use in adults and pediatric patients weighing 20 kg or more. Nuwellis emphasizes the importance of managing fluid overload, which is linked to increased mortality in pediatric patients.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:09 pm

ARCT

Japan's Ministry of Health, Labour and Welfare has approved ARCT-154, a COVID-19 vaccine developed by CSL and Arcturus Therapeutics. This approval could lead to increased demand for the vaccine in Japan and potentially other markets, reflecting positively on the involved companies.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:08 pm

PHAT

Phathom Pharmaceuticals, Inc. has announced the U.S. commercial availability of VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB) for the treatment of Erosive GERD and associated heartburn. VOQUEZNA has demonstrated superiority over lansoprazole in clinical trials and is available through major retail pharmacies and BlinkRx. The company is also preparing to launch VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK for H. pylori infection treatment in mid-December 2023.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:06 pm

ICCM

IceCure Medical announced the publication of a study in 'Cancers' showing the safety and efficacy of its ProSense system. The study reported a 92% disease-free survival rate at a median follow-up of 26.5 months.

Portfolio Pulse from Benzinga Newsdesk

November 28, 2023 | 1:06 pm